NCT03742258View on ClinicalTrials.gov

Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

March 13, 2019

Primary Completion Date

March 12, 2021

Study Completion Date

February 8, 2024

Conditions
Diffuse Large B-Cell LymphomaDiffuse Large B-Cell Lymphoma Activated B-Cell TypeDiffuse Large B-Cell Lymphoma Germinal Center B-Cell TypeDiffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedHigh Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 RearrangementsHigh Grade B-Cell Lymphoma, Not Otherwise SpecifiedT-Cell/Histiocyte-Rich Large B-Cell Lymphoma
Interventions
DRUG

Cyclophosphamide

Given IV

DRUG

Doxorubicin Hydrochloride

Given IV

DRUG

Prednisone

Given PO

BIOLOGICAL

Rituximab

Given IV

DRUG

Spleen Tyrosine Kinase Inhibitor TAK-659

Given PO

DRUG

Vincristine Sulfate

Given IV

Trial Locations (2)

60045

Northwestern Lake Forest Hospital, Lake Forest

60611

Northwestern University, Chicago

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Northwestern University

OTHER

NCT03742258 - Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma | Biotech Hunter | Biotech Hunter